Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104

Benzinga Newsdesk www.benzinga.com Negative 81.8%

Neg 81.8% Neu 0% Pos 0%

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.